Share
ST. LOUIS, MO – A proposed nationwide class-action settlement resolving claims that exposure to Roundup herbicides caused non-Hodgkin lymphoma (NHL) was filed today in the 22nd Judicial Circuit Court for the City of St. Louis, Missouri. The settlement would make up to $7.25 billion available to compensate individuals across the United States who were exposed to Roundup products and were diagnosed with NHL, as well as those exposed who are diagnosed in the future.
Roundup is manufactured by Monsanto, a global agrochemical company now owned by Bayer AG. Monsanto has faced litigation for more than a decade over allegations that Roundup’s active ingredient, glyphosate, causes NHL and that the company failed to adequately warn users of the risk. Since 2015, only 24 trials have reached a verdict, with Monsanto prevailing in the majority of these cases.
“This proposed settlement represents a historic step toward bringing justice and financial relief to thousands of people across the country who developed non-Hodgkin lymphoma after exposure to Roundup,” said Christopher A. Seeger of Seeger Weiss LLP, proposed counsel for the proposed class. “After years of intense litigation and uncertainty, this agreement provides a clear, streamlined path to compensation—delivering speed, transparency, and security for those already suffering, while preserving future claimants’ rights amid the pending Supreme Court review. We also expect the compensation provided to class members to be higher than the per-claim averages in other recent Monsanto settlements.”
The proposed settlement comes as the U.S. Supreme Court has agreed to hear Monsanto’s appeal asserting that federal law preempts state law failure-to-warn claims involving the Roundup label, where the Environmental Protection Agency has not required any warning for NHL. On January 16, 2026, the Court granted certiorari, agreeing to review the case, with a decision expected as early as June 2026. If Monsanto prevails, many Roundup claims could be dismissed or limited nationwide.
After years of hard-fought litigation, including a multi-district litigation, tens of thousands of state court cases and prior attempts to resolve claims, this proposed settlement seeks to deliver prompt, guaranteed compensation while preserving important exit rights for claimants. In addition to avoiding U.S. Supreme Court review, it also eliminates the risks of a bankruptcy filing by Monsanto and additional years of waiting for a trial date or resolution.
The settlement would create a nationwide class consisting of:
- Current claimants: Individuals exposed to Roundup in the United States who have already been diagnosed with non-Hodgkin lymphoma
- Future claimants: Individuals exposed to Roundup before the settlement date who have not yet been diagnosed but are diagnosed with NHL in the future.
Monsanto would fund the settlement with up to $7.25 billion, including nearly $3 billion paid in the first five years, to provide early and meaningful compensation to those already diagnosed. In addition to these benefits, the compensation provided to class members is expected to be higher than the per-claim averages in recent Monsanto settlements.
The settlement class includes individuals who were exposed to Roundup products in the United States before the settlement date through application, purchase, participation or proximity.
Compensation would be awarded through a transparent, tiered grid system based on objective criteria, including type of exposure (occupational or residential), age at diagnosis, and type of non-Hodgkin lymphoma (aggressive or indolent).
The settlement provides certainty, speed, and flexibility, while preserving the right of class members to exit the program and return to court under defined circumstances if payments are delayed, funds are exhausted, or future claimants reject their awards.
Average awards range from approximately $165,000 for younger occupational claimants with aggressive NHL to $10,000 for claimants first diagnosed at age 78 or older, with individual awards adjusted upward or downward based on claim-specific factors such as strength of exposure proof and severity of treatment. Additional compensation is available through Extraordinary Circumstances and Extraordinary Residential Exposure funds.
The settlement also includes Quick-Pay and Exigency Awards, allowing certain eligible claimants to receive expedited payments, even before the settlement becomes fully effective, totaling up to $300 million that Monsanto must pay regardless of whether the settlement ultimately takes effect.
The settlement will be subject to court approval. If preliminary approval is granted, a court-supervised notice program will inform potential class members of their rights, including how to submit claims or opt out.
The settlement agreement, Q&A, and other documents filed today will be sent separately once stamped copies are available.
Prior results do not guarantee or predict a similar outcome in any future matter.
###
One of the nation’s preeminent plaintiffs’ law firms, Seeger Weiss is best known for multidistrict mass torts and class actions in both state and federal court. From offices in New York, New Jersey, and Pennsylvania, the firm has represented over thousands of individuals, organizations, and states and local municipalities across the U.S. that have been injured or defrauded on a massive scale. Since its founding in 1999, Seeger Weiss has led many of the most complex and high-profile cases in the country, including the National Prescription Opiate Litigation, 3M Combat Arms Earplug Products Liability Litigation, and the Philips Recalled CPAP, Bi-Level Pap, and Mechanical Ventilator Litigation.